Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis

Annals of the Rheumatic Diseases

Volumn 77, Issue 5, 2018, Pages 720-727

  Aggarwal, Rohit ^a   Marder, Galina ^b   Koontz, Diane Carol ^a   Nandkumar, Preeya ^b   Qi, Zengbiao ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Northwell Health   (United States)

Author keywords

autoimmune diseases; dermatomyositis; polymyositis

Indexed keywords

CHOLESTEROL; CORTICOTROPIN; PREDNISONE; HORMONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AVASCULAR NECROSIS; BODY WEIGHT GAIN; CALCINOSIS; CLINICAL ARTICLE; DEPRESSION; DERMATOMYOSITIS; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GEL; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE CONTUSION; INJECTION SITE RASH; INSOMNIA; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE STRENGTH; MUSCULOSKELETAL DISEASE ASSESSMENT; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; POLYMYOSITIS; PRIORITY JOURNAL; PROOF OF CONCEPT; PROSPECTIVE STUDY; RESTLESSNESS; SIDE EFFECT; SINUS TACHYCARDIA; SINUSITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; VISUAL ANALOG SCALE; CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; DERMATOMYOSITIS; FEMALE; GELS; HORMONES; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; POLYMYOSITIS; PROOF OF CONCEPT STUDY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85045906038     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212047     Document Type: Article

References (54)

1. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010;6:129-37.
2. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011;11:6-13.
3. Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012;6:133-9.
4. Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
5. Van Der Meulen M F, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-21.
6. Labbé O, Desarnaud F, Eggerickx D, et al. Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry 1994;33:4543-9.
7. Oddis C V, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
8. Aggarwal R, Rider LG, Ruperto N, et al. 2016 American college of rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis 2017;76:792-801.
9. Aggarwal R, Rider LG, Ruperto N, et al. 2016 American college of rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2017;69:898-910.
10. Rider LG, Aggarwal R, Pistorio A, et al. 2016 American college of rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2017;69:911-23.
11. Rider LG, Aggarwal R, Pistorio A, et al. 2016 American college of rheumatology/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis 2017;76:782-91.
12. Montero-Melendez T. ACTH: the forgotten therapy. Semin Immunol 2015;27:216-26.
13. Levine T, Malone J, et al. H.p. Acthar® gel in dermatomyositis and polymyositis treatment registry: an interim analysis. J Neurol Disord 2016;4.
14. Patel A, Seely G, Aggarwal R. Repository corticotropin injection for treatment of idiopathic infammatory myopathies. Case Rep Rheumatol 2016;2016:1-4.
15. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2011;8:122-8.
16. Gettig J, Cummings J P, Matuszewski K. H.P. Acthar gel and cosyntropin review: clinical and fnancial implications. P T 2009;34:250-7.
17. Miller H, Newell DJ, Ridley A. Multiple sclerosis. treatment of acute exacerbations with corticotrophin (A.C.t.H.). Lancet 1961;2:1120-2.
18. Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181-97.
19. Gutman AB, Yut F. Effects of adrenocorticotropic hormone (ACtH) in gout. Am J Med 1950;9:24-30.
20. Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACtH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med 1950;85:545-666.
21. Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone effcacy in gouty arthritis. Arthritis Rheum 2002;46:2765-75.
22. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of infammation. ScientifcWorldJournal 2010;10:1840-53.
23. Catania A, Gatti S, Colombo G, et al. Targeting melanocortin receptors as a novel strategy to control infammation. Pharmacol Rev 2004;56:1-29.
24. Dores RM. Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of robert Schwyzer: a thirty-year retrospective. Ann N Y Acad Sci 2009;1163:93-100.
25. Xing Y, Parker CR, Edwards M, et al. ACtH is a potent regulator of gene expression in human adrenal cells. J Mol Endocrinol 2010;45:59-68.
26. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACtH) gel. Drug Des Devel Ther 2011;5:147-53.
27. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACtH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97:375-9.
28. Simsarian J P, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther 2011;5:381-9.
29. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006;27:736-49.
30. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004;101:279-83.
31. Baughman R P, Barney JB, O'Hare L, et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med 2016;110:66-72.
32. Decker DA, Grant C, Oh L, et al. Immunomodulatory effects of H.p. Acthar Gel on B cell development in the nZB/W F1 mouse model of systemic lupus erythematosus. Lupus 2014;23:802-12.
33. Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus 2014;23:905-12.
34. Li X, Golubovsky J, Hui-Yuen J, et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients. F1000Res 2015;4:1103.
35. Zhou Y, Lower EE, Li H, et al. Sarcoidosis patient with lupus pernio and infiximab-induced myositis: response to Acthar gel. Respir Med Case Rep 2016;17:5-7.
36. Khanna D, Khanna P P, Fitzgerald JD, et al. 2012 American college of rheumatology guidelines for management of gout. part 2: therapy and antiinfammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61.
37. Daoussis D, Antonopoulos I, Yiannopoulos G, et al. ACtH as frst line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 2013;80:291-4.
38. Daoussis D, Antonopoulos I, Yiannopoulos G, et al. ACtH as frst line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine 2014;81:98-100.
39. Doi K, Hu X, Yuen PS, et al. Ap214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008;73:1266-74.
40. Böhm M, Grässel S. Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. Endocr Rev 2012;33:623-51.
41. Böhm M, Raghunath M, Sunderkötter C, et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem 2004;279:6959-66.
42. Cornish J, Callon KE, Mountjoy KG, et al. Alpha-melanocyte-stimulating hormone is a novel regulator of bone. Am J Physiol Endocrinol Metab 2003;284:E1181-E1190.
43. Grässel S, Opolka A, Anders S, et al. The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinfammatory cytokines and extracellular matrix components. Arthritis Rheum 2009;60:3017-27.
44. Zaidi M, Sun L, Robinson LJ, et al. ACtH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sci USA 2010;107:8782-7.
45. Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor nF-kappa B activation induced by various infammatory agents. J Immunol 1998;161:2873-80.
46. Star RA, Rajora N, Huang J, et al. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci USA 1995;92:8016-20.
47. Catania A, Gerloni V, Procaccia S, et al. The anticytokine neuropeptide alpha-melanocyte-stimulating hormone in synovial fuid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Neuroimmunomodulation 1994;1:321-8.
48. Hughes S, Smith ME. Upregulation of the pro-opiomelanocortin gene in spinal motoneurones in muscular dystrophy in mice. Neurosci Lett 1993;163:205-7.
49. Smith ME, Hughes S. poMC neuropeptides and their receptors in the neuromuscular system of wobbler mice. J Neurol Sci 1994;124 Suppl:56-8.
50. An JJ, Rhee Y, Kim SH, et al. Peripheral effect of alpha-melanocyte-stimulating hormone on fatty acid oxidation in skeletal muscle. J Biol Chem 2007;282:2862-70.
51. Cossu G, Cusella-de Angelis MG, Senni MI, et al. Adrenocorticotropin is a specifc mitogen for mammalian myogenic cells. Dev Biol 1989;131:331-6.
52. de Angelis L, Cusella-de Angelis MG, Bouchè M, et al. ACtH-like peptides in postimplantation mouse embryos: a possible role in myoblast proliferation and muscle histogenesis. Dev Biol 1992;151:446-58.
53. Patel HB, Bombardieri M, Sampaio AL, et al. Anti-infammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. Faseb J 2010;24:4835-43.
54. Kaneva MK, Kerrigan MJ, Grieco P, et al. Chondroprotective and anti-infammatory role of melanocortin peptides in tnF-α activated human C-20/A4 chondrocytes. Br J Pharmacol 2012;167:67-79.